Vitamin D: Cancer and Differentiation

Vitamin D

Volumn 2, Issue , 2005, Pages 1571-1597

  van Leeuwen, Johannes P T M ^a   Pols, Huibert A P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24344460692     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012252687-9/50093-0     Document Type: Chapter

References (372)

1. Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR 1,25-dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993, 53:3712-3718.
2. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 1994, 31:191-202.
3. Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M Immunohistochemical analysis of 1,25-dihydroxyvitamin D3 receptors, estrogen, and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res 2002, 22:2261-2267.
4. Evans SR, Nolla J, Hanfelt J, Shabahang M, Nauta RJ, Shchepotin IB Vitamin D receptor expression as a predictive marker of biological behavior in human colorectal cancer. Clin Cancer Res 1998, 4:1591-1595.
5. Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem Cytochem 1998, 46:1335-1337.
6. Friedrich M, Villena-Heinsen C, Tilgen W, Schmidt W, Reichrat J, Axt-Fliedner R Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res 2002, 22:1919-1924.
7. Eisman JA, Suva LJ, Sher E, Pearce PJ, Funder JW, Martin TJ Frequency of 1,25-dihydroxyvitamin D3 receptor in human breast cancer. Cancer Res 1981, 41:5121-5124.
8. Freake HC, Abeyasekera G, Iwasaki J, Marcocci C, MacIntyre I, McClelland RA, Skilton RA, Easton DF, Coombes RC Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices. Cancer Res 1984, 44:1677-1681.
9. Eisman JA, Suva LJ, Martin TJ Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers. Cancer Res 1986, 46:5406-5408.
10. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res 1987, 47:6793-6799.
11. Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 1991, 51:239-244.
12. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, Easton DF, Pharoah PP Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002, 62:3052-3057.
13. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
14. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA, Haussler MR Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 2002, 299:730-738.
15. Zinser GM, Sundberg JP, Welsh J Vitamin D(3) receptor ablation sensitizes skin to chemically-induced tumorigenesis. Carcinogenesis 2002, 23:2103-2109.
16. Garland CF, Garland FC Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol 1980, 9:227-231.
17. Garland CF, Comstock GW, Garland FC, Helsing KJ, Shaw EK, Gorham ED Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2:1176-1178.
18. Garland CF, Garland FC, Gorham ED Can colon cancer incidence and death rates be reduced with calcium and vitamin D?. Am J Clin Nutr 1991, 54:193S-201S.
19. Garland FC, Garland CF, Gorham ED, Young JF Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990, 19:614-622.
20. Schwartz GG, Hulka BS Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990, 10:1307-1311.
21. Gorham ED, Garland FC, Garland CF Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990, 19:820-824.
22. Hanchette CL, Schwartz GG Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70:2861-2869.
23. Ainsleigh HG Beneficial effects of sun exposure on cancer mortality. Prev Med 1993, 22:132-140.
24. Studzinski GP, Moore DC Sunlight-can it prevent as well as cause cancer?. Cancer Res 1995, 55:4014-4022.
25. Grant WB An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
26. de Gruijl FR, Longstreth J, Norval M, Cullen AP, Slaper H, Kripke ML, Takizawa Y, van der Leum JC Health effects from stratospheric ozone depletion and interactions with climate change. Photochem Photobiol. Sci. 2003, 2:16-28.
27. Albert MR, Ostheimer KG The evolution of current medical and popular attitudes toward ultraviolet light exposure: Part 2. J Am Acad Dermatol 2003, 48:909-918.
28. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC Outcome in prostate, cancer associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001, 22:1343-1347.
29. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer 2001, 85:1504-1509.
30. Bodiwala D, Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Ramachandran S, Fryer AA, Strange RC Susceptibility to prostate cancer:studies on interactions between UVR exposure and skin type. Carcinogenesis 2003, 24:711-717.
31. Jablonski NG, Chaplin G Skin deep. Sci Am 2002, 287:74-81.
32. Jacobson EA, James KA, Newmark HL, Carroll KK Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)-anthracene in female Srague-Dawley rats. Cancer Res 1989, 49:6300-6303.
33. Barger-Lux MJ, Heaney RP The role of calcium intake in preventing bone fragility, hypertension, and certain cancers. J Nutr 1994, 124:1406S-1411S.
34. Newmark HL Vitamin D adequacy: a possible relationship to breast cancer. Adv Exp Med Biol 1994, 364:109-114.
35. Kleibeuker JH, van der MR, de Vries EG Calcium and vitamin D: possible protective agents against colorectal cancer?. Eur J Cancer 1995, 31 A:1081-1084.
36. Garland CF, Garland FC, Gorham ED Calcium and vitamin D, Their potential roles in colon and breast cancer prevention. Ann NY Acad Sci 1999, 889:107-119.
37. McCullough ML, Robertson AS, Rodriguez C, Jacobs EJ, Chao A, Carolyn J, Calle EE, Willett WC, Thun MJ Calcium, vitamin D, dairy products, and risk of colorectal cancer in the cancer prevention study II nutrition cohort (United States). Cancer Causes Control 2003, 14:1-12.
38. Simard A, Vobecky J, Vobecky JS Vitamin D deficiency and cancer of the breast: an unprovocative ecological hypothesis. Can J Public Health 1991, 82:300-303.
39. Pence BC, Richard BC, Lawlis RS, Kuratko CN Effects of dietary calcium and vitamin D3 on tumor promotion in mouse skin. Nutr Cancer 1991, 16:171-181.
40. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
41. Tuohimaa P, Lyakhovich A, Aksenov N, Pennanen P, Syvala H, Lou YR, Ahonen M, Hasan T, Pasanen P, Blauer M, Manninen T, Miettinen S, Vilja P, Ylikomi T Vitamin D and prostate cancer. J Steroid Biochem Mol Biol 2001, 76:125-134.
42. La Vecchia C, Braga C, Negri E, Franceschi S, Russo A, Conti E, Falcini F, Giacosa A, Montella M, Decarli A Intake of selected micronutrients and risk of colorectal cancer. Int J Cancer 1997, 73:525-530.
43. Lipkin M, Reddy B, Newmark H, Lamprecht SA Dietary factors in human colorectal cancer. Annu Rev Nutr 1999, 19:545-586.
44. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000, 6:507-515.
45. Kallay E, Pietschmann P, Toyokuni S, Bajna E, Hahn P, Mazzucco K, Bieglmayer C, Kato S, Cross HS Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation, and DNA damage. Carcinogenesis 2001, 22:1429-1435.
46. Miller CW, Morosetti R, Campbell MJ, Mendoza S, Koeffler HP Integrity of the 1,25-dihydroxyvitamin D3 receptor in bone, lung, and other cancers. Mol Carcinog 1997, 19:254-257.
47. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996, 56:4108-4110.
48. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997, 89:166-170.
49. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res 1998, 58:1620-1623.
50. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999, 105:281-287.
51. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000, 60:305-308.
52. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr J 2001, 48:543-549.
53. Hamasaki T, Inatomi H, Katoh T, Ikuyama T, Matsumoto T Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol Int 2002, 68:226-231.
54. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 2002, 47:413-418.
55. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM Vitamin D receptor start codon polymorphism (fokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2003, 12:23-27.
56. Watanabe M, Fukutome K, Murata M, Uemura H, Kubota Y, Kawamura J, Yatani R Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese. Anticancer Res 1999, 19:4511-4514.
57. Blazer DG, Umbach DM, Bostick RM, Taylor JA Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 2000, 27:18-23.
58. Gsur A, Madersbacher S, Haidinger G, Schatzl G, Marberger M, Vutuc C, Micksche M Vitamin D receptor gene polymorphism and prostate cancer risk. Prostate 2002, 51:30-34.
59. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Koike H, Nakazato H, Okugi H, Hasumi M, Fukabori Y, Kurokawa K, Yamanaka H Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol 2003, 10:261-266.
60. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003, 88:928-932.
61. Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer 1999, 83:723-726.
62. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-East Sweden Breast Cancer Group. Cancer Res 1999, 59:2332-2334.
63. Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, Haile RW, Coetzee GA Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000, 11:25-30.
64. Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001, 85:171-175.
65. Hou MF, Tien YC, Lin GT, Chen CJ, Liu CS, Lin SY, Huang TJ Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002, 74:1-7.
66. Schondorf T, Eisberg C, Wassmer G, Warm M, Becker M, Rein DT, Gohring UJ Association of the vitamin D receptor genotype with bone metastases in breast cancer patients. Oncology 2003, 64:154-159.
67. Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, Smith N, Pharoah PD, Luben RN, Easton DF, Ponder BA No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 1999, 20:2131-2135.
68. Ingles SA, Wang J, Coetzee GA, Lee ER, Frankl HD, Haile RW Vitamin D receptor polymorphisms and risk of colorectal adenomas (United States). Cancer Causes Control 2001, 12:607-614.
69. Slatter ML, Yakumo K, Hoffman M, Neuhausen S Variants of the VDR gene and, risk of colon cancer (United States). Cancer Causes Control 2001, 12:359-364.
70. Peters U, McGlynn KA, Chatterjee N, Gunter E, Garcia-Closas M, Rothman N, Sinha R Vitamin D calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001, 10:1267-1274.
71. Ramachandran S, Fryer AA, Smith AG, Lear JT, Bowers B, Hartland AJ, Whiteside JR, Jones PW, Strange RC Basal cell carcinomas: association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics 2001, 11:247-254.
72. Ikuyama T, Hamasaki T, Inatomi H, Katoh T, Muratani T, Matsumoto T Association of vitamin D receptor gene polymorphism with renal cell carcinoma in Japanese. Endocr J 2002, 49:433-438.
73. Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000, 6:498-504.
74. Speer G, Dworak O, Cseh K, Bori Z, Salamon D, Torok I, Winkler G, Vargha P, Nagy Z, Takacs I, Kucsera M, Lakatos P Vitamin D receptor gene BsmI polymorphism correlates with erbB-2/HER-2 expression in human rectal cancer. Oncology 2000, 58:242-247.
75. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998, 7:385-390.
76. Kim HS, Newcomb PA, Ulrich CM, Keener CL, Bigler J, Farin FM, Bostick RM, Potter JD Vitamin D receptor polymorphism and the risk of colorectal adenomas: evidence of interaction with dietary vitamin D and calcium. Cancer Epidemiol Biomarkers Prev 2001, 10:869-874.
77. Wong HL, Seow A, Arakawa K, Lee HP, Yu MC, Ingles SA Vitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese. Carcinogenesis 2003, 24:1091-1095.
78. Durrin LK, Haile RW, Ingles SA, Coetzee GA Vitamin D receptor 3′-untranslated region polymorphisms: lack of effect on mRNA stability. Biochim Biophys Acta 1999, 1453:311-320.
79. Colston K, Colston MJ, Feldman D 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
80. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981, 78:4990-4994.
81. Miyaura C, Abe E, Kuribayashi T, Tanaka H, Konno K, Nishii Y, Suda T 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 1981, 102:937-943.
82. Suda T, Miyaura C, Abe E, Kuroki T Modulation of cell differentiation, immune responses and tumor promotion by vitamin D compounds 1986, 1-48. Elsevier, Amsterdam. W.A. Peck (Ed.).
83. Suda T, Takahashi N, Abe E Role of vitamin D in bone resorption. J Cell Biochem 1992, 49:53-58.
84. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N Modulation of osteoclast differentiation by local factors. Bone 1995, 17:87S-91S.
85. Wu JC, Smith MW, Lawson DE Time dependency of 1,25(OH)2D3 induction of calbindin mRNA and calbindin expression in chick enterocytes during their differentiation along the crypt-villus axis. Differentiation 1992, 51:195-200.
86. Honma Y, Hozumi M, Abe E, Konno K, Fukushima M, Hata S, Nishii Y, DeLuca HF, Suda T 1 alpha,25-dihydroxyvitamin D3 and 1 alpha-hydroxyvitamin D3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 1983, 80:201-204.
87. Sato T, Takusagawa K, Asoo N, Konno K Antitumor effect of 1 alpha-hydroxyvitamin D3. Tohoku J Exp Med 1982, 138:445-446.
88. Wood AW, Chang RL, Huang MT, Uskokovic M, Conney AH 1 alpha,25-dihydroxyvitamin D3 inhibits phorbol esterdependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 1983, 116:605-611.
89. Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T Inhibition of tumor promotion in mouse skin by 1 alpha, 25-dihydroxyvitamin D3. Cancer Res 1985, 45:5426-5430.
90. Eisman JA, Barkla DH, Tutton PJ Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987, 47:21-25.
91. Cohen SM, Saulenas AM, Sullivan CR, Albert DM Further studies of the effect of vitamin D on retinoblastoma. Inhibition with 1,25-dihydroxycholecalciferol. Arch Ophthalmol 1988, 106:541-543.
92. Eisman JA, Koga M, Sutherland RL, Barkla DH, Tutton PJ 1,25-dihydroxyvitamin D3 and the regulation of human cancer cell replication. Proc Soc Exp Biol Med 1989, 191:221-226.
93. Colston KW, Berger U, Coombes RC Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, 1:188-191.
94. Albert DM, Marcus DM, Gallo JP, O'Brien JM The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci 1992, 33:2354-2364.
95. Belleli A, Shany S, Levy J, Guberman R, Lamprecht SA A protective role of 1,25-dihydroxyvitamin D3 in chemically-induced rat colon carcinogenesis. Carcinogenesis 1992, 13:2293-2298.
96. Iino Y, Yoshida M, Sugamata N, Maemura M, Ohwada S, Yokoe T, Ishikita T, Horiuchi R, Morishita Y 1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res Treat 1992, 22:133-140.
97. Haq M, Kremer R, Goltzman D, Rabbani SA A vitamin D analog (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 1993, 91:2416-2422.
98. Tsuchiya H, Morishita H, Tomita K, Ueda Y, Tanaka M Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma. J Orthop Res 1993, 11:122-130.
99. Young MR, Halpin J, Hussain R, Lozano Y, Djordjevic A, Devata S, Matthews JP, Wright MA Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion Metastasis 1993, 13:169-177.
100. Cohen-Solal ME, Bouizar Z, Denne MA, Graulet AM, Gueris J, Bracq S, Jullienne A, De Vernejoul MC 1,25 dihydroxyvitamin D and dexamethasone decrease in vivo Walker carcinoma growth, but not parathyroid hormone-related protein secretion. Horm Metab Res 1995, 27:403-407.
101. Young MR, Ihm J, Lozano Y, Wright MA, Prechel MM Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 1995, 41:37-45.
102. Young MR, Lozano Y, Ihm J, Wright MA, Prechel MM Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett 1996, 104:153-161.
103. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50:999-1006.
104. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB 1089. Cancer Epidemiol Biomarkers Prev 1999, 8:241-248.
105. Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL, Gill PS Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000, 96:3188-3194.
106. Polek TC, Murthy S, Blutt SE, Boehm MF, Zou A, Weigel NL, Allegretto EA Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate 2001, 49:224-233.
107. Kunakornsawat S, Rosol TJ, Capen CC, Reddy GS, Binderup L, Inpanbutr N Effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and its analogs (EB1089 and analog V) on canine adenocarcinoma (CAC-8) in nude mice. Biol Pharm Bull 2002, 25:642-647.
108. Oades GM, Dredge K, Kirby RS, Colston KW Vitamin D receptor-dependent antitumor effects of 1,25-dihydroxyvitamin D3 and two synthetic analogs in three in vivo models of prostate cancer. BJU Int 2002, 90:607-616.
109. Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. Anticancer Res 2003, 23:283-289.
110. Pols HA, Birkenhager JC, van Leeuwen JP Vitamin D analogs: from molecule to clinical application. Clin Endocrinol (Oxf) 1994, 40:285-292.
111. Bouillon R, Okamura WH, Norman AW Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-257.
112. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic M, Koeffler HP 1,25-dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemic mice. Proc Natl Acad Sci USA 1990, 87:3929-3932.
113. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991, 129:832-837.
114. Colston K, Mackay AG, Chandler S, Binderup L, Coombes RC Novel vitamin D analogs suppress tumour growth in vivo. Vitamin D: Gene regulation, structure-function analysis and clinical application 1991, 465-466. De Gruyter. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
115. Oikawa T, Yoshida Y, Shimamura M, Ashino-Fuse H, Iwaguchi T, Tominaga T Antitumor effect of 22-oxa-1alpha,25-dihydroxyvitamin D3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethyl-benz[a]anthracene. Anticancer Drugs 1991, 2:475-480.
116. Colston KW, Chander SK, Mackay AG, Coombes RC Effects of synthetic vitamin D analogs on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992, 44:693-702.
117. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes RC EB1089: a new vitamin D analog that inhibits the growth of breast cancer cells in vivo and in vivo. Biochem Pharmacol 1992, 44:2273-2280.
118. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K Antitumor effect of 22-oxa-calcitriol, a non-calcemic analog of calcitriol in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993, 53:2534-2537.
119. Anzano MA, Smith JM, Uskokovic MR, Peer CW, Mullen LT, Letterio JJ, Welsh MC, Shrader MW, Logsdon DL, Driver CL 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analog) for prevention of breast cancer in the rat. Cancer Res 1994, 54:1653-1656.
120. Tanaka Y, Wu AY, Ikekawa N, Iseki K, Kawai M, Kobayashi Y Inhibition of HT-29 human colon cancer growth under the renal capsule of severe combined immunodeficient mice by an analog of 1,25-dihydroxyvitamin D3, DD-003. Cancer Res 1994, 54:5148-5153.
121. Otoshi T, Iwata H, Kitano M, Nishizawa Y, Morii H, Yano Y, Otani S, Fukushima S Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analog of 1 alpha, 25-dihydroxyvitamin D3. Carcinogenesis 1995, 16:2091-2097.
122. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR 1,25-dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 1995, 46:365-369.
123. Wali RK, Bissonnette M, Khare S, Hart J, Sitrin MD, Brasitus TA 1 alpha,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analog of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethaneinduced colonic tumorigenesis. Cancer Res 1995, 55:3050-3054.
124. Akhter J, Chen X, Bowrey P, Bolton EJ, Morris DL Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 1997, 40:317-321.
125. Van Weelden K, Flanagan L, Binderup L, Tenniswod M, Welsh J Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinology 1998, 139:2102-2110.
126. Nickerson T, Huynh H Vitamin D analog EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 1999, 160:223-229.
127. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL A calcitriol analog, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000, 60:779-782.
128. Dawson DG, Gleiser J, Zimbric ML, Darjatmoko SR, Lindstrom MJ, Strugnell SA, Albert DM Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag trangenic mice. Ophthalmology 2003, 110:835-839.
129. Mehta RG, Hussain EA, Mehta RR, Das Gupta TK Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of vitamin D. Mutat Res 2003, 523-524:253-264.
130. Cunningham D, Gilchrist NL, Cowan RA, Forrest GJ, McArdle CS, Soukop M Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Br Med J (Clin Res Ed) 1985, 291:1153-1155.
131. Raina V, Cunningham D, Gilchrist N, Soukop M Alfacalcidol is a nontoxic, effective treatment of follicular, small-cleaved cell lymphoma. Br J Cancer 1991, 63:463-465.
132. Koeffler HP, Hirji K, itri L 1,25-dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 1985, 69:1399-1407.
133. Kelsey SM, Newland AC, Cunningham J, Makin HL, Coldwell RD, Mills MJ, Grant IR Sustained hematological response to high-dose oral alfacalcidol in patients with myelodysplastic syndromes. Lancet 1992, 340:316-317.
134. French LE, Ramelet AA, Saurat JH Remission of cutaneous T-cell lymphoma with combined calcitriol and acitretin. Lancet 1994, 344:686-687.
135. Majewski S, Skopinska M, Bollag W, Jablonska S Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 1994, 344:1510-1511.
136. Thomsen K Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment. Lancet 1995, 345:1583.
137. French LE, Saurat JH Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol. Lancet 1995, 346:376.
138. Bagot M Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol. Lancet 1995, 346:376-377.
139. Gross C, Stamey T, Hancock S, Feldman D Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998, 159:2035-2039.
140. Beer TM, Lemmon D, Lowe BA, Henner WD High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003, 97:1217-1224.
141. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res 1999, 5:1339-1345.
142. Beer TM, Munar M, Henner WD A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91:2431-2439.
143. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Combes RC Topical calcipotriol treatment in advanced breast cancer. Lancet 1991, 337:701-702.
144. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC A phase I study of the vitamin D analog EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 1998, 78:6-13.
145. Evans TR, Colston KW, Lofts FJ, Cunningham D, Anthoney DA, Gogas H, de Bono JS, Hamberg KJ, Skov T, Mansi JL A phase II trial of the vitamin D analog Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. Br J Cancer 2002, 86:680-685.
146. Majewski S, Szmurlo A, marczak M, Jablonska S, Bollag W Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett 1993, 75:35-39.
147. Bollag W, Majewski S, Jablonska S Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia 1994, 8:1453-1457.
148. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W Retinoids, interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines. RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett 1995, 89:117-124.
149. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143:2508-2514.
150. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1995, 36:83-87.
151. Ding I, Sun JZ, Fenton B, Liu WM, Kimsely P, Okunieff P, Min W Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Res 2001, 61:526-531.
152. Marneros AG, Olsen BR The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol 2001, 20:337-345.
153. Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N Effects of vitamin D(3)-binding protein-derived macrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 2002, 94:1311-1319.
154. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003, 5:32-40.
155. Nowicka D, Zagozdzon R, Majewski S, Marczak M, Jablonska S, Bollag W Calcitriol enhances antineoplastic and antiangiogenic effects of interleukin-12. Arch Dermatol Res 1998, 290:696-700.
156. Hansen CM, Frandsen TL, Brunner N, Binderup L 1 alpha,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994, 12:195-202.
157. Koli K, Keski-Oja J 1alpha,25-dihydroxyvitamin D3 and its analogs down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ 2000, 11:221-229.
158. Arguello F, Baggs RB, Frantz CN A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988, 48:6876-6881.
159. Agha FP, Norman A, Hirschl S, Klein R Paget's disease. Coexistence with metastatic carcinoma. N Y State J Med 1976, 76:734-735.
160. Orr W, Varani J, Gondex MK, Ward PA, Mundy GR Chemotactic responses of tumor cells to products of resorbing bone. Science 1979, 203:176-179.
161. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55:3551-3557.
162. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
163. Mackey SL, Heymont JL, Kronenberg HM, Demay MB Vitamin D receptor binding to the negative human parathyroid hormone vitamin D response element does not require the retinoid x receptor. Mol Endocrinol 1996, 10:298-305.
164. Moseley JM, Gillespie MT Parathyroid hormonerelated protein. Crit Rev Clin Lab Sci 1995, 32:299-343.
165. Sebag M, Henderson J, Goltzman D, Kremer R Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro. Am J Physiol 1994, 267:C723-C730.
166. Werkmeister JR, Merryman JI, McCauley LK, Horton JE, Capen CC, Rosol TJ
167. Kremer R, Karaplis AC, Henderson J, Gulliver W, Banville D, Hendy GN, Goltzman D Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. Effect of growth factors and 1,25 dihydroxyvitamin D3 on gene expression and secretion. J Clin Invest 1991, 87:884-893.
168. Henderson J, Sebag M, Rhim J, Goltzman D, Kremer R Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res 1991, 51:6531.
169. Yu J, Papavasiliou V, Rhim J, Goltzman D, Kremer R Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 1995, 6:101-108.
170. Falzon M The noncalcemic vitamin D analogs EB 1089 and 22-oxacalcitriol interact with the vitamin D receptor and suppress parathyroid hormone-related peptide gene expression. Mol Cell Endocrinol 1997, 127:99-108.
171. Inoue D, Matsumoto T, Ogata E, Ikeda K 22-oxacalcitriol, a noncalcemic analog of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T-cell lymphotrophic virus, type I-infected T-cells. J Biol Chem 1993, 268:16730-16736.
172. Liu B, Goltzman D, Rabbani SA Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. Endocrinology 1993, 132:1658-1664.
173. Tovar SV, Falzon M Regulation of PTH-related protein gene expression by vitamin D in PC-3 prostate cancer cells. Mol Cell Endocrinol 2002, 190:115-124.
174. Shen X, Falzon M Parathyroid hormone-related protein up-regulates integrin expression via an intracrine pathway in PC-3 prostate cancer cell. Regul Pept 2003, 113:17-29.
175. Shen X, Falzon M PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile. Mol Cell Endocrinol 2003, 199:165-177.
176. El Abdaimi K, Papavasiliou V, Rabbani SA, Rhim JS, Goltzman D, Kremer R Reversal of hypercalcemia with the vitamin D analog EB1089 in a human model of squamous cancer. Cancer Res 1999, 59:3325-3328.
177. Endo K, Ichikawa F, Uchiyama Y, Katsumata K, Ohkawa H, Kumaki K, Ogata E, Ikeda K Evidence for the uptake of a vitamin D analog (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-relate peptide gene in vivo. J Biol Chem 1994, 269:32693-32699.
178. Merryman JI, Capen CC, McCauley LK, Werkmeister JR, Suter MM, Rosol TJ Regulation of parathyroid hormone-related protein production by a squamous carcinoma cell line in vitro. Lab Invest 1993, 69:347-354.
179. Kunakornsawat S, Rosol TJ, Capen CC, Middleton RP, Hannah SS, Inpanbutr N Effects of 1,25(OH) 2D3, EB 1089, and analog V on PTHrP production, PTHrP mRNA expression and cell growth in SCC 2/88. Anticancer Res 2001, 21:3355-3363.
180. Chatterjee M Vitamin D and genomic stability. Mutat Res 2001, 475:69-87.
181. Saha BK, Bishayee A, Kanjilal NB, Chatterjee M 1Alph, 25-dihydroxyvitamin D3 inhibits hepatic chromosomal aberrations, DNA strand breaks and specific DNA adducts during rat hepatocarcinogenesis. Cell Mol Life Sci 2001, 58:1141-1149.
182. Akutsu N, Lin R, Bastien Y, Bestawros A, Enepekides DJ, Black MJ, White JH Regulation of gene expression by 1alpha, 25-dihydroxyvitamin D3 and its analog EB 1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol Endocrinol 2001, 15:1127-1139.
183. Gartel AL, Shchors K Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003, 283:17-21.
184. Karmali R, Bhalla AK, Farrow SM, Williams MM, Lal S, Lydyard PM, O'Riordan JL Early regulation of c-myc mRNA by 1,25-dihydroxyvitamin D3 in human myelomonocytic U937 cells. J Mol Endocrinol 1989, 3:43-48.
185. Koizumi T, Nakao Y, Kawanishi M, Maeda S, Sugiyama T, Fujita T Suppression of c-myc mRNA expression by steroid hormones in HTLV-I-infected T-cell line, KH-2. Int J Cancer 1989, 44:701-706.
186. Moore DC, Carter DL, Studzinski GP Inhibition by 1,25 dihydroxyvitamin D3 of c-myc down-regulation and DNA fragmentation in cytosine arabinoside-induced erythroid differentiation of K562 cells. J Cell Physiol 1992, 151:539-548.
187. Sebag M, Henderson J, Rhim J, Kremer R Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression. J Biol Chem 1992, 267:12162-12167.
188. Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD, Malviya VK, Malone JM, Deppe G Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993, 4:201-208.
189. Kasukabe T, Okabe-Kado J, Hozumi M, Honma Y Inhibition by interleukin 4 of leukemia inhibitory factorinterleukin 6-, and dexamethasone-induced differentiation of mouse myeloid leukemia cells: role of c-myc and jun B protooncogenes. Cancer Res 1994, 54:592-597.
190. Taoka T, Collins ED, Irino S, Norman AW 1,25(OH)2-vitamin D3 mediated changes in mRNA for c-myc and 1,25(OH)2D3 receptor in HL-60 cells and related subclones. Mol Cell Endocrinol 1993, 95:51-57.
191. Stio M, Celli A, Treves C Synergistic antiproliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J Steroid Biochem Mol Biol 2001, 77:213-222.
192. Vink-van Wijngaarden T, Pols HA, Buurman CJ, van den Bemd GJ, Dorssers LC, Birkenhager JC, van Leeuwen JP Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogs and tamoxifen. Cancer Res 1994, 54:5711-5717.
193. Hulla W, Kallay E, Krugluger W, Peterlik M, Cross HS Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: relation to c-myc-oncogene and vitamin-D-receptor expression. Int J Cancer 1995, 62:711-716.
194. Trydal T, Lillehaug JR, Aksnes L, Aarskog D Regulation of cell growth, c-myc mRNA, and 1,25-(OH)2 vitamin D3 receptor in C3H/10T1/2 mouse embryo fibroblasts by calcipotriol and 1,25-(OH)2 vitamin D3. Acta Endocrinol (Copenh) 1992, 126:75-79.
195. Paatero GI, Trydal T, Karlstedt KA, Aarskog D, Lillehaug JR Time-course study of 1,25-(OH)2-vitamin D3 induction of homologous receptor and c-myc in nontransformed and transformed C3H/10T1/2 cell clones. Int J Biochem 1994, 26:367-374.
196. Mahonen A, Pirskanen A, Maenpaa PH Homologous and heterologous regulation of 1,25-dihydroxyvitamin D-3 receptor mRNA levels in human oste osarcoma cells. Biochim Biophys Acta 1991, 1088:111-118.
197. van den Bemd GJ, Pols HA, Birkenhager JC, Kleinekoort WM, van Leeuwen JP Differential effects of 1,25-dihydroxy-vitamin D3-analogs on osteoblast-like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol 1995, 55:337-346.
198. Brelvi ZS, Christakos S, Studzinski GP Expression of monocyte-specific oncogenes c-fos and c-fms in HL 60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Lab Invest 1986, 55:269-275.
199. Huh N, Satoh M, Nose K, Abe E, Suda T, Rajewsky MF, Kuroki T 1 alpha, 25-dihydroxyvitamin D3 induces anchorage-independent growth and c-Ki-ras expression of BALB/3T3 and NIH/3T3 cells. Jpn J Cancer Res 1987, 78:99-102.
200. Lasky SR, Iwata K, Rosmarin AG, Caprio DG, Maizel AL Differential regulation of JunD by dihydroxycholecalciferol in human chronic myelogenous leukemia cells. J Biol Chem 1995, 270:19676-19679.
201. Khare S, Bolt MJ, Wali RK, Skarosi SF, Roy HK, Niedziela S, Scaglione-Sewell B, Aquino B, Abraham C, Sitrin MD, Brasitus TA, Bissonnette M 1,25 dihydroxyvitamin D3 stimulates phospholipase C-gamma in rat colonocytes: role of c-Src in PLC-gamma activation. J Clin Invest 1997, 99:1831-1841.
202. Khare S, Bissonnette M, Wali R, Skarosi S, Boss GR, von Lintig FC, Scaglione-Sewell B, Sitrin MD, Brasitus TA 1,25-dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60 (c-src) and RhoA. Am J Physiol 1999, 276:G1005-G1015.
203. Johansen C, Kragballe K, Henningsen J, Westergaard M, Kristiansen K, Iversen L 1 alpha, 25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fral, and c-Jun expression in human keratinocytes. J Invest Dermatol 2003, 120:561-570.
204. Lasky SR, Posner MR, Iwata K, Santos-Moore A, Yen A, Samuel V, Clark J, Maizel AL Characterization of a vitamin D3-resistant human chronic myelogenous leukemia cell line. Blood 1994, 84:4283-4294.
205. Fan FS, Yu WC 1,25-dihydroxyvitamin D3 suppresses cell growth, DNA synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line. Cancer Invest 1995, 13:280-286.
206. Yen A, Chandler S, Forbes ME, Fung YK, T'Ang A, Pearson R Coupled down-regulation of the RB retinoblastoma and c-myc genes antecedes cell differentiation: possible role of RB as a "status quo" gene. Eur J Cell Biol 1992, 57:210-221.
207. Yen A, Varvayanis S Late dephosphorylation of the RB protein in G2 during the process of induced cell differentiation. Exp Cell Res 1994, 214:250-257.
208. Kobayashi T, Hashimoto K, Yoshikawa K Growth inhibition of human keratinocytes by 1,25-dihydroxyvitamin D3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 1993, 196:487-493.
209. Ehinger M, Bergh G, Olofsson T, Baldetorp B, Olsson I, Gullberg U Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25-dihydroxycholecalciferol in leukemic U-937 cells. Blood 1996, 87:1064-1074.
210. Davoust N, Wion D, Chevalier G, Garabedian M, Brachet P, Couez D Vitamin D receptor stable transfection restores the susceptibility to 1,25-dihydroxyvitamin D3 cytotoxicity in a rat glioma resistant clone. J Neurosci Res 1998, 52:210-219.
211. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP 20-epi-vitamin D3 analogs: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 1995, 55:2822-2830.
212. Pepper C, Thomas A, Hoy T, Milligan D, Bentley P, Fegan C The vitamin D3 analog EB 1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood 2003, 101:2454-2460.
213. Lee TH, Pelletier J Functional characterization of WT1 binding sites within the human vitamin D receptor gene promoter. Physiol Genomics 2001, 7:187-200.
214. Chen KS, DeLuca HF Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta 1994, 1219:26-32.
215. Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J J Biol Chem 1999 tiIdentification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression, 274:21645-21650.
216. Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, Yodoi J Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life 2001, 52:29-33.
217. Ikarashi M, Takahashi Y, Ishii Y, Nagata T, Asai S, Ishikawa K Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res 2002, 22:4045-4048.
218. Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K, Asai S Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 2002, 9:75-79.
219. Schulze PC, De Keulenaer GW, Yoshioka J, Kassik KA, Lee RT Vitamin D3 up-regulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res 2002, 91:689-695.
220. Wang Y, De Keulenaer GW, Lee RT Vitamin D(3) up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem 2002, 277:26496-26500.
221. Han SH, Jeon JH, Ju HR, Jung U, Kim KY, Yoo HS, Lee YH, Song KS, Hwang HM, Na YS, Yang Y, Lee KN, Choi I VDUP1 up-regulated by TGF-betal and 1,25-dihydroxyvitamin D(3) inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 2003, 22:4035-4046.
222. Song H, Cho D, Jeon JH, Han SH, Hur DY, Kim YS, Choi I Vitamin D(3) up-regulating protein 1 (VDUP1) antisense DNA regulates tumorigenicity and melanogenesis of murine melanoma cells via regulating the expression of fas ligand and reactive oxygen species. Immunol Lett 2003, 86:235-247.
223. Ward JO, McConnell MJ, Carlile GW, Pandolfi PP, Licht JD, Freedman LP The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor. Blood 2001, 98:3290-3300.
224. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, Pelicci PG, Nervi C, Ruthardt M AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 2002, 62:7050-7058.
225. Yamamoto Y, Sakamoto M, Fujii G, Kanetaka K, Asaka M, Hirohashi S Cloning and characterization of a novel gene, DRH1, down-regulated in advanced human hepatocellular carcinoma. Clin Cancer Res 2001, 7:297-303.
226. Jakob F, Homann D, Adamski J Expression and regulation of aromatases and 17 beta-hydroxysteroid dehydrogenase type 4 in human THP 1 leukemia cells. J Steroid Biochem Mol Biol 1995, 55:555-563.
227. Hughes SV, Robinson E, Bland R, Lewis HM, Stewart PM, Hewison M 1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 1997, 138:3711-3718.
228. Hughes PJ, Twist LE, Durham J, Choudhry MA, Drayson M, Chandraratna R, Michell RH, Kirk CJ, Brown G Up-regulation of steroid sulphatase activity in Hl60 promyelocytic cells by retinoids and 1alpha,25-dihydroxyvitamin D3. Biochem J 2001, 355:361-371.
229. Enjuanes A, Garcia-Giralt N, Supervia A, Nogues X, Mellibovsky L, Garbonell J, Grinberg D, Balcells S, Diez-Perez A Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur J Endocrinol 2003, 148:519-526.
230. Reichman TW, Albanell J, Wang X, Moore MA, Studzinski GP Down-regulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J Cell Biochem 1997, 67:13-23.
231. Rots NY, Liu M, Anderson EC, Freedman LP A differential screen for ligand-regulated genes: idenification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 1998, 18:1911-1918.
232. Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson J, Boguski MS, Lashkari D, Shalon D, Botstein D, Brown PO The transcriptional program in the response of human fibroblasts to serum. Science 1999, 283:83-87.
233. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, Matese JC, Perou CM, Hurt MM, Brown PO, Botstein D Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002, 13:1977-2000.
234. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, Diamandis EP, Hudson TJ, White JH Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB 1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002, 16:1243-1256.
235. Krishnan AV, Peehl DM, Feldman D Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003, 88:363-371.
236. Walker PR, Kwast-Welfeld J, Gourdeau H, Leblanc J, Neugebauer W, Sikorska M Relationship between apoptosis and the cell cycle in lymphocytes: roles of protein kinase C, tyrosine phosphorylation, and AP1. Exp Cell Res 1993, 207:142-151.
237. Denmeade SR, Lin XS, Isaacs JT Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
238. Kerr JF, Wyllie AH, Currie AR Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
239. Evans SR, Soldatenkov V, Shchepotin EB, Bogrash E, Shchepotin IB Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int J Oncol 1999, 14:979-985.
240. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348:334-336.
241. Korsmeyer SJ, McDonnell TJ, Nunez G, Hockenbery D, Young R Bcl-2: B cell life, death, and neoplasia. Curr Top Microbiol Immunol 1990, 166:203-207.
242. Xu HM, Tepper CG, Jones JB, Fernandez CE, Studzinski GP 1,25-dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. Exp Cell Res 1993, 209:367-374.
243. James SY, Mackay AG, Colston KW Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol 1995, 14:391-394.
244. Danielsson C, Torma H, Vahlquist A, Carlberg C Positive and negative interaction of 1,25-dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int J Cancer 1999, 81:467-470.
245. Guzey M, Kitada S, Reed JC Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002, 1:667-677.
246. Baudet C, Perret E, Delpech B, Kaghad M, Brachet P, Wion D, Caput D Differentially expressed genes in C6.9 glioma cells during vitamin D-induced cell death program. Cell Death Differ 1998, 5:116-125.
247. Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhager JC, van Leeuwen JP Combined effects of 1,25-dihydroxyvitamin D3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1994, 29:161-168.
248. Wallington LA, Bunce CM, Durham J, Brown G Particular combinations of signals, by retinoic acid and 1 alpha, 25 dihydroxyvitamin D3, promote apoptosis of HL60 cells. Leukemia 1995, 9:1185-1190.
249. Wu YL, Jiang XR, Lillington DM, Allen PD, Newland AC, Kelsey SM 1,25-dihydroxyvitamin D3 protects human leukemic cells from tumor necrosis factor-induced apoptosis via inactivation of cytosolic phospholipase A2. Cancer Res 1998, 58:633-640.
250. Witcher M, Yang X, Pater A, Tang SC BAG-1 p50 isoform interacts with the vitamin D receptor and its cellular oxerexpression inhibits the vitamin D pathway. Exp Cell Res 2001, 265:167-173.
251. Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A, Peng X Vitamin D target proteins: function and regulation. J Cell Biochem 2003, 88:238-244.
252. Bikle DD, Pillai S Vitamin D, calcium, and epidermal differentiation. Endocr Rev 1993, 14:3-19.
253. Hosoi J, Abe E, Suda T, Kuroki T Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res 1985, 45:1474-1478.
254. van Leeuwen JP, van Steenbrugge GJ, Veldscholte J, van den Bemd GJ, Oomen MHA, Pols HA, Birkenhager JC Growth regulation of three sublines of the human prostatic carcinoma line LNCaP by an interrelated action of 1,25-dihydroxyvitamin D3 and androgens. Vitamin D, pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical application 1994, 510-511. de Gruyter. A.W. Norman, R. Bouillon, M. Thomasset (Eds.).
255. Esquenet M, Swinnen JV, Heyns W, Verhoeven G Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate 1996, 28:182-194.
256. Zhao XY, Ly LH, Peehl DM, Feldman D 1alpha, 25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997, 138:3290-3298.
257. Hedlund TE, Moffatt KA, Uskokovic MR, Miller GJ Three synthetic vitamin D analogs induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 1997, 3:1331-1338.
258. Frappart L, Falette N, Lefebvre MF, Bremond A, Vauzelle JL, Saez S In vitro study of effects of 1,25 dihydroxyvitamin D3 on the morphology of human breast cancer cell line Bt.20. Differentation 1989, 40:63-69.
259. Nagasaki T, Hino M, Inaba M, Nishizawa Y, Morii H, Otani S Inhibition by 1alpha,25-dihydroxyvitamin D3 of activin A-induced differentiation of murine erythroleukemic F5-5 cells. Arch Biochem Biophys 1997, 343:181-187.
260. Lefebvre MF, Guillot C, Crepin M, Saez S Influence of tumor-derived fibroblasts and 1,25-dihydroxyvitamin D3 on growth of breast cancer cell lines. Breast Cancer Res Treat 1995, 33:189-197.
261. Rotello RJ, Lieberman RC, Purchio AF, Gerschenson LE Coordinated regulation of apoptosis and cell proliferation by transforming growth factor heta 1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991, 88:3412-3415.
262. Alexandrow MG, Moses HL Transforming growth factor beta 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription. Cancer Res 1995, 55:3928-3932.
263. Laiho M, Decaprio JA, Ludlow JW, Livingston DM, Massague J Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990, 62:175-185.
264. Simboli-Campbell M, Welsh J 1,25-dihydroxyvitamin D3 1995 Coordinate regulator of active cell death and proliferation in MCF-7 breast cancer cells. Apoptosis in hormone dependent cancers 1995, 181-200. Springer-Verlag. M. Tenniswood, H. Michna (Eds.).
265. Kim HJ, Abdelkader N, Katz M, McLane JA 1,25-dihydroxyvitamin D3 enhances antiproliferative effect and transcription of TGF-beta on human keratinocytes in culture. J Cell Physiol 1992, 151:579-587.
266. Koli K, Keski-Oja J Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and-beta 2 in cultured murine keratinocytes. Growth Factors 1993, 8:153-163.
267. Finkelman RD, Linkhart TA, Mohan S, Lau KH, Baylink DJ, Bell NH Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor beta in rat bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 1991, 88:3657-3660.
268. Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 2001, 188:383-393.
269. Vink-van Wijngaarden T, Pols HA, Buurman CJ, Birkenhager JC, van Leeuwen JP Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analog EB 1089. Eur J Cancer 1996, 32A:842-848.
270. Drivdahl RH, Loop SM, Andress DL, Ostenson RC IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin D3. Prostate 1995, 26:72-79.
271. Velez-Yanguas MC, Kalebic T, Maggi M, Kappel CC, Letterio J, Uskokovic M, Helman LJ 1 alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531) modulation of insulin-like growth factor-binding protein-3 and induction of differentiation and growth arrest in a human osteosarcoma cell line. J Clin Endocrinol Metab 1996, 81:93-99.
272. Moriwake T, Tanaka H, Kanzaki S, Higuchi J, Seino Y 1,25-dihydroxyvitamin D3 stimulates the secretion of insulin-like growth factor binding protein 3 (IGFBP-3) by cultured human osteosarcoma cells. Endocrinology 1992, 130:1071-1073.
273. Nakao Y, Hilliker S, Baylink DJ, Mohan S Studies on the regulation of insulin-like growth factor binding protein 3 secretion in human osteosarcoma cells in vitro. J Bone Miner Res 1994, 9:865-872.
274. Koga M, Eisman JA, Sutherland RL Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Res 1988, 48:2734-2739.
275. Falette N, Frappart L, Lefebvre MF, Saez S Increased epidermal growth factor receptor level in breast cancer cells treated by 1,25-dihydroxyvitamin D3. Mol Cell Endocrinol 1989, 63:189-198.
276. Welsh J Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem Cell Biol 1994, 72:537-545.
277. Byrne IM, Flanagan L, Tenniswood MP, Welsh J Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene. Endocrinology 2000, 141:2829-2836.
278. Wietzke JA, Welsh J Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003, 84:149-157.
279. Sminoff P, Liel Y, Gnainsky J, Shany S, Schwartz B The protective effect of estrogen against chemically-induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999, 11:255-264.
280. Ahonen MH, Zhuang YH, Aine R, Ylikomi T, Tuohimaa P Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. Int J Cancer 2000, 86:40-46.
281. Zhao XY, Ly Lh, Peehl DM, Feldman D Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology 1999, 140:1205-1212.
282. Miyaura C, Abe E, Honma Y, Hozumi M, Nishii Y, Suda T Cooperative effect of 1 alpha,25-dihydroxyvitamin D3 and dexamethasone in inducing differentiation of mouse myeloid leukemia cells. Arch Biochem Biophys 1983, 227:379-385.
283. Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst 1998, 90:134-141.
284. Bernardi RJ, Trump DL, Yu WD, Mcguire TF, Hershberger PA, Johnson CS Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 2001, 7:4164-4173.
285. Ziegler R, Kasperk C Glucocorticoid-induced osteoporosis: prevention and treatment. Steroids 1998, 63:344-348.
286. Koga M, Sutherland RL Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol 1991, 39:455-460.
287. Moore TB, Sidell N, Chow VJ, Medzoyan RH, Huang JI, Yamashiro JM, Wada RK Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid. J Pediatr Hematol Oncol 1995, 17:311-317.
288. Bunce CM, Wallington LA, Harrison P, Williams GR, Brown G Treatment of HL60 cells with various combinations of retinoids and 1 alpha,25 dihydroxyvitamin D3 results in differentiation towards neutrophils or monocytes or a failure to differentiate and apoptosis. Leukemia 1995, 9:410-418.
289. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone, and vitamin D3 signalling. Nature 1992, 355:446-449.
290. Matsui T, Takahashi R, Mihara K, Nakagawa T, Koizumi T, Nakao Y, Sugiyama T, Fujita T Cooperative regulation of c-myc expression in differentiation of human promyelocytic leukemia induced by recombinant gamma-interferon and 1,25-dihydroxyvitamin D3. Cancer Res 1985, 45:4366-4371.
291. Morel PA, Manolagas SC, Provvedini DM, Wegmann DR, Chiller JM Interferon gamma-induced IA expression in WEHI-3 cells is enhanced by the presence of 1,25-dihydroxyvitamin D3. J Immunol 1986, 136:2181-2186.
292. Kelsey SM, Makin HL, MacEy MG, Newland AC Gamma interferon augments functional and phenotypic characteristics of vitamin D3-induced monocytoid differentiation in the U937 human leukaemic cell line. Leuk Res 1990, 14:1027-1033.
293. Kelsey SM, Coldwell RD, Makin HL, Syndercombe-Court, Newland AC Neopterin release by myeloid leukemic cells can be synergistically augmented by 1,25-dihydroxyvitamin D3 in combination with gamma interferon or granulocyte-macrophage colony stimulating factor. J Steroid Biochem Mol Biol 1994, 48:95-99.
294. Kasukabe T, Okabe-Kado J, Honma Y, Hozumi M Interleukin-4 inhibits the differentiation of mouse myeloid leukemia M1 cells induced by dexamethasone, D-factor/leukemia inhibitory factor and interleukin-6, but not by 1 alpha,25-dihydroxyvitamin D3. FEBS Lett 1991, 291:181-184.
295. Kasukabe T, Okabe-Kado J, Honma Y, Hozumi M Interleukin 4 potentiates the antiproliferative effect of 1 alpha, 25-dihydroxyvitamin D3 on mouse monocytic leukemia cells but antagonizes the antiproliferative effects of interferon alpha, beta and interleukin 6. Leuk Res 1992, 16:1191-1196.
296. Hassan HT, Tsiriyotis C, Maurer HR, Spandidos DA Recombinant human interleukin-3 opposes the effects of vitamins A and D on HL-60 human myeloid leukaemia cells. Anticancer Res 1992, 12:821-825.
297. Prechel MM, Lozano Y, Wright MA, Ihm J, Young MR Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells. Cancer Immunol Immunother 1996, 42:213-220.
298. Koren R, Rocker D, Kotestiano O, Liberman UA, Ravid A Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species. J Steroid Biochem Mol Biol 2000, 73:105-112.
299. Katakami Y, Nakao Y, Katakami N, Koizumi T, Ogawa R, Yamada H, Takai Y, Fujita T Cooperative effects of tumor necrosis factor-alpha and 1,25-dihydroxyvitamin D3 on growth inhibition, differentiation, and c-myc reduction in human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1988, 152:1151-1157.
300. Rocker D, Ravid A, Liberman UA, Garach-Jehoshua O, Koren R 1,25-dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 1994, 106:157-162.
301. Hassan HT, Eliopoulos A, Maurer HR, Spandidos DA Recombinant human GM-CSF enhances the antiproliferative activity of vitamin D in MCF-7 human breast cancer clonogenic cells. Eur J Cancer 1992, 28A:1588-1589.
302. Kelsey SM, Makin HL, Newland AC Functional significance of induction of differentiation in human myeloid leukaemic blasts by 1,25-dihydroxyvitamin D3 and GM-CSF. Leuk Res 1992, 16:427-434.
303. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001, 20:1860-1872.
304. Gaschott T, Werz O, Steinmeyer A, Steinhilber D, Stein J Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 2001, 288:690-696.
305. Gaschott T, Wachtershauser A, Steinhilber D, Stein J 1,25-dihydroxycholecalciferol enhances butyrate-induced p21 (Waf1/Cip 1) expression. Biochem Biophys Res Commun 2001, 288:80-85.
306. Bizzarri M, Cucina A, Valente MG, Tagliaferri F, Borrelli V, Stipa F, Cavallaro A Melatonin and vitamin D(3) increase TGF-beta(1) release and induce growth inhibition in breast cancer cell cultures. J Surg Res 2003, 110:332-337.
307. Tong WM, Kallay E, Hofer H, Hulla W, Manhardt T, Peterlik M, Cross HS Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur J Cancer 1998, 34:2119-2125.
308. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 1991, 51:2848-2853.
309. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 1999, 59:862-867.
310. Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz DA The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 2000, 63:1-10.
311. Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 2001, 47:429-436.
312. Danilenko M, Wang X, Studzinski GP Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents. J Natl Cancer Inst 2001, 93:1224-1233.
313. Danilenko M, Wang Q, Wang X, Levy J, Sharoni Y, Studzinski GP Carnosic
314. Gewirtz DA, Gupta MS, Sundaram S Vitamin D3 and vitamin D3 analogs as an adjunct to cancer chemotherapy and radiotherapy. Curr Med Chem Anti Canc Agents 2002, 2:683-690.
315. Polar MK, Gennings C, Park M, Gupta MS, Gewirtz DA Effect of the vitamin D(3) analog ILX 23-7553 on apoptosis and sensitivity to fractionated radiation in breast tumor cells and normal human fibroblasts. Cancer Chemother Pharmacol 2003, 51:415-421.
316. Sundaram S, Sea A, Feldman S, Strawbridge R, Hoopes PJ, Demidenko E, Binderup L, Gewirtz DA The combination of a potent vitamin D(3) analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 2003, 9:2350-2356.
317. Dokoh S, Donaldson CA, Haussler MR Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor. Cancer Res 1984, 44:2103-2109.
318. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995, 1:997-1003.
319. Hedlund TE, Moffatt KA, Miller GJ Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996, 137:1554-1561.
320. Jensen SS, Madsen MW, Lukas J, Bartek J, Binderup L Sensitivity to growth suppression by 1alpha,25-dihydroxyvitamin D(3) among MCF-7 clones correlates with Vitamin D receptor protein induction. J Steroid Biochem Mol Biol 2002, 81:123-133.
321. Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H, Iida M Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor and cyclin-dependent kinase inhibitors, p21 and p27. Nephrol Dial Transplant 2003, 18(Suppl. 3):III9-III12.
322. Zinser GM, McEleney K, Welsh J Characterization of mammary tumor cell lines from wild type and vitamin D(3) receptor knockout mice. Mol Cell Endocrinol 2003, 200:67-80.
323. Xu HM, Kolla SS, Goldenberg NA, Studzinski GP Resistance to 1,25-dihydroxyvitamin D3 of a deoxycytidine kinase-deficient variant of human leukemia HL60 cells. Exp Cell Res 1992, 203:244-250.
324. Narvaez CJ, VanWeelden K, Byrne I, Welsh J Characterization of a vitamin D3-resistant MCF-7 cell line. Endocrinology 1996, 137:400-409.
325. Iwata K, Kouttab N, Ogata H, Morgan JW, Maizel AL, Lasky SR Differential regulation of vitamin D receptors in clonal populations of a chronic myelogenous leukemia cell line. Exp Cell Res 1996, 225:143-150.
326. Narvaez CJ, Byrne BM, Romu S, Valrance M, Welsh J Induction of apoptosis by 1,25-dihydroxyvitamin D(3) in MCF-7 Vitamin D(3)-resistant variant can be sensitized by TPA. J Steroid Biochem Mol Biol 2003, 84:199-209.
327. Hansen CM, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L MCF-7/VD(R): a new vitamin D resistant cell line. J Cell Biochem 2001, 82:422-436.
328. Wajchmann HJ, Rathod B, Song S, Xu H, Wang X, Uskokovic MR, Studzinski GP Loss of deoxcytidine kinase expression and tetraploidization of HL60 cells following long-term culture in 1,25-dihydroxyvitamin D3. Exp Cell Res 1996, 224:312-322.
329. Solomon C, Sebag M, White JH, Rhim J, Kremer R Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J Biol Chem 1998, 273:17573-17578.
330. Prufer K, Schroder C, Hegyi K, Barsony J Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol. Mol Endocrinol 2002, 16:961-976.
331. Zhuang SH, Burnstein KL Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.
332. Chen H, Hu B, Allegretto EA, Adams JS The vitamin D response element-binding protein. A novel dominant-negative regulator of vitamin D-directed transactivation. J Biol Chem 2000, 275:35557-35564.
333. Chen H, Hewison M, Hu B, Adams JS Heterogeneous nuclear ribonucleoprotein (hmRNP) binding to hormone response elements: a cause of vitamin D resistance. Proc Natl Acad Sci USA 2003, 100:6109-6114.
334. Chen TL, Hauschka PV, Feldman D Dexamethasone increases 1,25-dihydroxyvitamin D3 receptor levels and augments bioresponses in rat osteoblast-like cells. Endocrinology 1986, 118:1119-1126.
335. Ly LH, Zhao XY, Holloway L, Feldman D Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140:2071-2076.
336. Campbell MJ, Drayson MT, Durham J, Wallington L, Siu-Caldera ML, Reddy GS, Brown G Metabolism of 1alpha,25(OH)2D3 and its 20-epi analog integrates clonal expansion, maturation, and apoptosis during HL-60 cell differentiation. Mol Cell Endocrinol 1999, 149:169-183.
337. Quack M, Mork HC, Binderup E, Kissmeyer AM, Carlberg C Metabolism of the vitamin D3 analog EB1089 alters receptor complex formation and reduces promoter selectivity. Br J Pharmacol 1998, 125:607-614.
338. Dilworth FJ, Williams GR, Kissmeyer AM, Nielsen JL, Binderup E, Calverley MJ, Makin HL, Jones G The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology 1997, 138:5485-5496.
339. van den Bemd GC, Dilworth FJ, Makin HL, Prahl JM, DeLuca HF, Jones G, Pols HA, van Leeuwen JP Contribution of several metabolites of the vitamin D analog 20-epi-22-oxa-24a,26a,27a-tri-homo-1,25-(OH)(2) vitamin D(3) (KH 1060) to the overall biological activity of KH1060 by a shared mechanism of action. Biochem Pharmacol 2000, 59:621-627.
340. Taniyama T, Wanibuchi H, Salim EI, Yano Y, Otani S, Nishizawa Y, Morii H, Fukushima S Chemopreventive effect of 24R,25-dihydroxyvitamin D(3) in N, N′-dimethylhydrazine-induced rat colon carcinogenesis. Carcinogenesis 2000, 21:173-178.
341. Farhan H, Wahala K, Cross HS Genistein inhibits Vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 2003, 84:423-429.
342. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000, 25:144-146.
343. Cross HS, Bareis P, Hofer H, Bischof MG, Bajna E, Kriwanek S, Bonner E, Peterlik M 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66:287-292.
344. Bareis P, Kallay E, Bischof MG, Bises G, Hofer H, Potzi C, Manhardt T, Bland R, Cross HS Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3). Exp Cell Res 2002, 276:320-327.
345. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, Moss SF, Kurihara N, Fan K, Yang K, Lipkin M Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev 2002, 11:113-119.
346. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003, 88:315-322.
347. Ogose A, Kawashima H, Morita O, Hotta T, Umezu H, Endo N Increase in serum 1,25-dihydroxyvitamin D and hypercalcemia in a patient with inflammatory myofibroblastic tumor. J Clin Pathol 2003, 56:310-312.
348. Baier R, Grauer A, Lazaretti-Castro M, Ziegler R, Raue F Differential effects of 1,25-dihydroxyvitamin D3 on cell proliferation and calcitonin gene expression. Endocrinology 1994, 135:2006-2011.
349. Ohta M, Okabe T, Ozawa K, Urabe A, Takaku F 1 alpha,25-dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett 1985, 185:9-13.
350. Mitsuhashi T, Morris RC, Ives HE 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991, 87:1889-1895.
351. Edelson JD, Chan S, Jassal D, Post M, Tanswell AK Vitamin D stimulates DNA synthesis in alveolar type-II cells. Biochim Biophys Acta 1994, 1221:159-166.
352. Lutzow-Holm C, De Angelis P, Grosvik H, Clausen OP 1,25-dihydroxyvitamin D3 and the vitamin D analog KH1060 induce hyperproliferation in normal mouse epidermis. A BrdUrd/DNA flow cytometric study. Exp Dermatol 1993, 2:113-120.
353. Gniadecki R A vitamin D analog KH 1060 activates the protein kinase C-c-fos signaling pathway to stimulate epidermal proliferation in murine skin. J Endocrinol 1994, 143:521-525.
354. Gniadecki R, Serup J Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogs of 1 alpha, 25-dihydroxyvitamin D3. Biochem Pharmacol 1995, 49:621-624.
355. Gniadecki R, Gniadecka M, Serup J The effects of KH 1060, a potent 20-epi analog of the vitamin D3 hormone, on hairless mouse skin in vivo. Br J Dermatol 1995, 132:841-852.
356. Hosoi J, Abe E, Suda T, Colburn NH, Kuroki T Induction of anchorage-independent growth of JB6 mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1986, 46:5582-5586.
357. Kitano Y, Ikeda N, Okano M Suppression of proliferation of human epidermal keratinocytes by 1,25-dihydroxyvitamin D3. Analysis of its effect on psoriatic lesion and of its mechanism using human keratinocytes in culture. Eur J Clin Invest 1991, 21:53-58.
358. Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D3. Endocrinology 1983, 113:1950-1957.
359. Kragballe K Vitamin D3 and skin diseases. Arch Dermatol Res 1992, 284(Suppl. 1):S30-S36.
360. Kuroki T, Sasaki K, Chida K, Abe E, Suda T 1 alpha, 25-dihydroxyvitamin D3 markedly enhances chemically-induced transformation in BALB 3T3 cells. Gann 1983, 74:611-614.
361. Sasaki K, Chida K, Hashiba H, Kamata N, Abe E, Suda T, Kuroki T Enhancement by 1 alpha,25-dihydroxyvitamin D3 of chemically induced transformation of BALB 3T3 cells without induction of ornithine decarboxylase or activation of protein kinase C1. Cancer Res 1986, 46:604-610.
362. Jones CA, Callaham MF, Huberman E Enhancement of chemical carcinogen-induced cell transformation in hamster embryo cells by 1 alpha,25-dihydroxycholecalciferol, the biologically active metabolite of vitamin D3. Carcinogenesis 1984, 5:1155-1159.
363. Wood AW, Chang RL, Huang MT, Baggiolini E, Partridge JJ, Uskokovic M, Conney AH Stimulatory effect of 1 alpha, 25-dihydroxyvitamin D3 on the formation of skin tumors in mice treated chronically with 7,12-dimethylbenz[a]anthracene. Biochem Biophys Res Commun 1985, 130:924-931.
364. Chang PL, Prince CW 1 alpha,25-dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate-induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells. Cancer Res 1993, 53:2217-2220.
365. Chang PL, Lee TF, Garretson K, Prince CW Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and-independent pathways. Clin Exp Metastasis 1997, 15:580-592.
366. Yamaoka K, Marion SL, Gallegos A, Haussler MR 1,25-dihydroxyvitamin D3 enhances the growth of tumors in athymic mice inoculated with receptor rich osteosarcoma cells. Biochem Biophys Res Commun 1986, 139:1292-1298.
367. Franceschi RT, James WM, Zerlauth G 1 alpha, 25-dihydroxyvitamin D3 specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J Cell Physiol 1985, 123:401-409.
368. Gronowicz G, Egan JJ, Rodan GA The effect of 1,25-dihydroxyvitamin D3 on the cytoskeleton of rat calvaria and rat osteosarcoma (ROS 17/2.8) osteoblastic cells. J Bone Miner Res 1986, 1:441-455.
369. Hodge BO, Kream BE Variable effects of dexamethasone on protein synthesis in clonal rat osteosarcoma cells. Endocrinology 1988, 122:2127-2133.
370. Abbadia Z, Amiral J, Trzeciak MC, Delmas PD, Clezardin P The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. FEBS Lett 1993, 335:161-166.
371. Huerta S, Irwin RW, Heber D, Go VL, Moatamed F, Huerta S, Ou C, Harris DM Intestinal polyp formation in the Apcmin mouse: effects of levels of dietary calcium and altered vitamin D homeostasis. Dig Dis Sci 2003, 48:870-876.
372. Sahpazidou D, Stravoravdi P, Toliou T, Geromichalos G, Zafiriou G, Natsis K, Gigis P Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1099, a vitamin D analog. Oncol Res 2003, 13:261-268.